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Centrioles are microtubule structures that form the two poles of the mitotic 
spindle and act as a structural scaffold upon which the primary cilium is built. To 
maintain the fidelity of these processes, centriole number is tightly regulated. 
When a cell possesses more than the canonical number of centrioles (4), a 
condition known as centriole amplification, it becomes susceptible to mitotic 
errors. Centriole amplification has been shown to promote spontaneous 
tumorigenesis in vivo and has been observed in a wide range of human tumors. 
Therefore, it was surprising to discover that centriole amplification induces a 
proliferative arrest in non-transformed cultured cells. A trimeric protein complex 
known as the PIDDosome has been shown to initiate a cell-cycle arrest in the 
presence of supernumerary centrioles. However, how a cell detects extra 
centrioles and relays this signal to the PIDDosome remains unknown.  
 To address this question, a genome-wide CRISPR/Cas9 knock-out screen 
was performed to identify genes required for the cell-cycle arrest following 
centriole amplification. We identified genes previously implicated in the response 
to extra centrioles, including all three components of the PIDDosome (PIDD1, 
CASP2, CRADD) as well as the downstream effectors P53 and P21. We also 
identified several novel regulators including ANKRD26, C2CD3 and SCLT1. 
Notably, these novel regulators are involved in the recruitment/formation of distal 
appendages, which are protein structures that decorate centrioles. Our data 
show that these structures also have a non-canonical role in triggering 
PIDDosome activation in response to centriole amplification. 
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 In normal cells, there is only one centriole that contains distal appendage 
structures; therefore, our data support a model in which multiple centrioles with 
distal appendages is the signal by which a cell ‘senses’ centriole amplification. 
This work highlights a novel role of distal appendages in the response to 
centriole amplification and shifts the focus from centrioles as merely structural 
platforms required to build centrioles and cilia toward these organelles acting as 
signaling centers in mammalian cells. 
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Chapter 1: Introduction 
 
Centrosomes are the main microtubule organizing centers of mammalian 
cells and are composed of two orthogonally arranged microtubule structures 
called centrioles surrounded by a proteinaceous material called the pericentriolar 
material or PCM.1,2 Centriole are involved in several cellular processes including 
organization of the microtubule network during interphase, formation of the 
bipolar spindle during mitosis and acting as a structural scaffold upon which the 
primary cilium is built. To ensure that these processes are carried out properly, 
centriole number is tightly controlled throughout the cell cycle3 so that each pre-
existing centriole undergoes only a single round of duplication, similar to the 
genetic material. Following mitosis, each daughter cell inherits a pair of 
centrioles. The two centrioles of this pair are structurally distinct from one 
another. One centriole is decorated with protein structures known as distal 
appendages and is referred to as the mature parent or mature mother centriole 
because it was built earlier than the immature parent centriole.4 The immature 
parent centriole was built in the previous cell cycle and lacks appendages on its 
distal end. The immature centriole will eventually acquire distal appendages 
when it becomes mature during the G1 phase of the next cell cycle. These 
appendage structures are required to dock the centriole at the membrane during 
the process of ciliogenesis.5 During the G1/S transition of the cell cycle, a new 
centriole begins to bud from the proximal end of each pre-existing centriole.6  
These new centrioles elongate throughout S-phase. During G2, the two original 
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centrioles separate from one another, producing two distinct centriole pairs or 
centrosomes. In mitosis, these structures become the two poles of the 
microtubule spindle which segregates chromosomes equally into the resulting 
daughter cells. Upon division the two centriole pairs are also partitioned into 
different daughter cells and the duplication process repeats. 
Errors in the duplication process can result in extra centrioles or centriole 
loss.1,7,8 Centriole loss is able to be tolerated in some species and cell 
populations, such as planarians or oocytes in humans.9,10 During mitosis, 
centrioles play a role in microtubule nucleation and spindle assembly, however, 
spindle assembly can occur through centriole independent microtubule 
nucleation.11 Although spindle assembly and chromosome segregation can occur 
in the absence of centrioles, mitoses in acentriolar cells are often result in 
segregation errors and aneuploidies.12 In concert, cultured mammalian cells 
experience a P53-depedent growth arrest following centriole loss, indicating that 
centrioles are required to maintain faithful chromosome segregation and 
continued growth. 
In acentriolar cells, spindle assembly and chromosome segregation is 
often delayed since cells must initiate microtubules nucleation by other means.11 
In the absence of centrioles, chromatin-dependent microtubule nucleation can 
compensate to help build the mitotic spindle.13 Since chromatin is sequestered in 
the nucleus, it does not have access to microtubule dimers and, therefore, 
cannot begin nucleating microtubules until nuclear envelope breakdown (NEB). 
Microtubules can also be generated from spindle microtubules in a centriole-
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independent manner14; however, this process requires a pre-existing microtubule 
scaffold. These factors contribute to the delay in spindle assembly in cells lacking 
centrioles. 
Genome-wide knock-out screens were used to identify how cells lacking 
centrioles could activate a P53-dependant arrest. These screens led to the 
identification of a signaling pathways containing USP28, 53BP1, P53 and P21.15–
17 Knocking out any of these four genes allows cells with centriole loss to 
continue proliferating. Despite being required to arrest cells following centriole 
loss none of these proteins exhibit centriolar localization. This indicates that 
centriole loss itself is likely not the trigger that initiates the cell-cycle arrest in 
acentriolar cells. Once mitotic duration exceeds a particular threshold, cultured 
cells experience a subsequent G1 arrest.15–17 Interestingly, all the genes 
identified as being required to arrest cells following centriole loss were also 
required for the growth arrest in cells with prolonged mitoses, regardless of 
whether centrioles were present or not.15–17 Therefore, this pathway has been 
referred to as ’the mitotic surveillance pathway’, since it appears to be sensing 
the extended mitotic time associated with centriole loss, rather than responding 
to changes in centriole number.  
How the mitotic surveillance pathway is activated following prolonged 
mitosis remains unclear. It is known that 53BP1 interacts with P53 in response to 
DNA double-strand breaks18 and that USP28 gets recruited to sites of DNA 
damage by 53BP1.19 However, the role of these proteins in the mitotic 
surveillance pathway is known to be independent of the DNA damage response, 
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suggesting that additional regulators of this pathway remain to be identified. One 
could imagine that once the mitotic surveillance pathway is activated, 53BP1 acts 
as an adaptor to between the deubiquitinase USP28 and P53. USP28 may then 
deubiquitinate and stabilize P53, which elicits a P21 mediated cell-cycle arrest. 
In addition to centriole loss, mitotic errors can result in an increase in 
centriole number. In cultured cells, the presence of supernumerary centrioles, a 
condition known as centriole amplification, is known to promote genetic instability 
through chromosome mis-segregation errors, chromosome breaks and DNA 
damage.20 Centriole amplification has also been observed in a wide range of 
human tumors and often correlated with higher cancer grade and poor patient 
prognosis.7 Additionally, centriole amplification has been proposed to promote 
metastasis via multiple mechanisms.21,22 Centriole amplification has been 
modeled in vivo by overexpressing the dose-dependent master regulator of 
centriole biogenesis polo-like kinase 4 (PLK4).23 In these models, the presence 
of supernumerary centrioles was shown to be sufficient to promote spontaneous 
tumorigenesis.24–26  
Centriole amplification is also observed in tetraploid cells, which contain 
twice the normal number of centrioles (4 vs. 2 in G1).21 Cells can become 
tetraploid by disrupting cytokinesis, which prevents daughter cells from 
separating from one another. Cytokinesis failure increases both the DNA content 
and centriole number in cells, whereas overexpression of PLK4 induces centriole 
amplification without a concurrent increase in genetic material. Like PLK4 
overexpression, however, the increase in centriole number in tetraploid cells can 
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lead to mitotic errors and DNA damage. Only tetraploid cells that spontaneously 
lose their extra centrioles are able to continue proliferating in culture27, 
highlighting the deleterious nature of centriole amplification. Additionally, 
tetraploidy induced through cytokinesis failure is able to promote tumorigenesis 
in P53-null cells.28 This is consistent with the observation that whole-genome 
duplication (tetraplodization) occurs in ~30 % of solid tumors.29 
Despite being found in a wide range of human tumors and being sufficient 
to promote tumorigenesis in animal models, centriole amplification leads to a cell 
cycle arrest in non-transformed cells in culture.30,31 Loss of P53 is able to 
overcome the growth arrest observed in these cells with extra centrioles. This is 
consistent with the dysregulation of P53 observed in the tumors from in vivo 
models of centriole amplification.24–26 These data indicate that the growth of cells 
with supernumerary centriole is disadvantageous and not tolerated in non-
transformed cells. 
Although the growth arrest following centriole loss and centriole 
amplification are both dependent on P53, USP28 and 53BP1 were found to be 
dispensable in response to extra centrioles.15 This indicates that there are two 
distinct pathways operating in cells that respond to centriole number; one 
responsible for arresting cells with too few centrioles and one that arrests cells 
with extra centrioles.  
Initial insight into how cells elicit a growth arrest following centriole 
amplification came from an siRNA screen performed in tetraploid cells containing 
twice canonical number of centrioles. This screen showed that the depletion of 
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the kinase LATS2 allowed tetraploid cells to overcome a G1 arrest. LATS2 is a 
component of the Hippo pathway, and was shown to facilitate P53 stabilization in 
the presence of supernumerary centrioles.32 The Hippo tumor suppressor 
pathway plays a role in cell proliferation and cell death and is known primarily for 
regulating organ size.33 The Hippo pathway controls cell growth through 
regulation of the transcriptional activators YAP/TAZ, which promote cell 
proliferation.34 When the Hippo pathway is activated, YAP/TAZ are 
phosphorylated by the kinase LATS2, which sequesters them in the cytoplasm 
and prevents transcription of their pro-proliferative targets. Phosphorylated 
(active) LATS2 has also been shown to inhibit the E3-ubiquitin ligase MDM2, 
which stabilizes P53. 
Tetraploid cells showed an increase in phosphorylated LATS2 and 
depletion of LATS2 in tetraploid cells was sufficient to overcome arrest.32 In 
tetraploid cells, the LATS2-dependent arrest appeared to be reliant on both its 
ability to inactivate YAP/TAZ and through stabilization of P53. It was shown that 
the activation of the Hippo pathway in response to centriole amplification was 
dependent on reduced RhoA activity rather than MST1/MST2, which are 
canonically known to function upstream of LATS2.32 This work implies a 
mechanism in which the presence of extra centrioles reduces RhoA activity, thus 
activating the Hippo pathway and inhibiting cell growth. 
In addition to the Hippo pathway, other pathways have been implicated in 
the response to centriole amplification. It has been shown that the PIDDosome 
becomes activated in cells with extra centrioles.30 The PIDDosome is a trimeric 
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protein complex composed of PIDD1, CRADD and Caspase-2 (CASP2).35 PIDD1 
and CRADD act as an activation platform for CASP2 by recruiting several 
inactive pro-CASP2 molecules so they can undergo proximity induced cleavage 
and activation.35,36 Once activated, CASP2 cleaves MDM2 and stabilizes P53, 
which initiates a proliferative arrest. 
CASP2 activation and MDM2 cleavage were both observed in cells that 
underwent cytokinesis failure.30 Furthermore, loss of PIDD1, CRADD or CASP2 
prevented MDM2 cleavage, indicating that this response was PIDDosome 
dependent. Inducing cytokinesis failure in cells lacking centrioles did not trigger 
activation of PIDDosome, indicating that this response is detecting the centriole 
amplification present in tetraploid cells rather than the increase in DNA content. 
Notably, activation of the PIDDosome was not observed by increasing mitotic 
duration or by inducing DNA damage. It was also shown that the core component 
of the PIDDosome, PIDD1, localizes to the mature mother centriole.30 This 
suggests that it may be the presence of extra mature mother centrioles that 
elicits PIDDosome activation in cells with centriole amplification, however how 
this could occur is not known. 
It is unclear whether the Hippo pathway or activation of the PIDDosome is 
predominantly responsible for arresting cells following centriole amplification or if 
these pathways work in concert to induce an arrest. Although activation of both 
the Hippo and PIDDosome pathways explain how P53 becomes stabilized 
following centriole amplification, it is still uncertain how the presence of extra 
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centrioles leads to such activation and if inactivation of these responses is 
sufficient to improve the long-term fitness of cells with centriole amplification. 
To address these questions, we performed a genome-wide CRISPR/Cas9 
knock-out screen to identify regulators of the response to centriole amplification 
in an unbiased way. The main goal of this work was to gain greater mechanistic 
insight into how cells ‘sense’ and respond to centriole amplification. Additionally, 









Chapter 2: Identification of novel regulators 
required to arrest cells following centriole 
amplification 
2.1 Introduction 
 Centriole amplification makes a cell susceptible to genetic instability.37 
Additionally, the continued growth of cells with extra centrioles has been shown 
to promote spontaneous tumorigenesis in vivo.24–26 To avoid propagation of 
genetically unstable cells, centriole amplification leads to a proliferative arrest in 
non-transformed, cultured cells. There have been several mechanisms proposed 
for how cells elicit a cell cycle arrest in the presence of extra centrioles, namely 
through the activation of the Hippo pathway or activation of the PIDDosome.30,32  
It has been shown that tetraploid cells containing twice the normal number 
of centrioles, stabilize P53 via activation of the Hippo pathway.32 The Hippo 
tumor suppressor pathway regulates cell proliferation primarily to control organ 
size during development. The Hippo pathway kinase LATS2 is activated in 
tetraploid cells. This activation leads to an inhibition of the YAP/TAZ 
transcriptional regulators, P53 stabilization and a proliferative arrest. LATS2 
activation was also observed when centriole amplification was induced by over-
expressing PLK4. These data indicate that centriole amplification may be 
initiating a cell-cycle arrest through activation of the Hippo pathway. 
The PIDDosome has also been shown to be activated in response to 
centriole amplification in tetraploid cells.30 The PIDDosome is a protein complex 
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responsible for activation of Caspase-2 (CASP2). This in turn leads to MDM2 
cleavage, P53 stabilization and expression of the cyclin-dependent kinase 
inhibitor, P21. This response was also shown to be centriole, rather than ploidy, 
dependent, providing another mechanism for the cell-cycle arrest following 
centriole amplification. 
Both of these proposed mechanisms involve P53 stabilization upon 
centriole amplification; however, it is not clear whether they work in concert to 
prevent proliferation or, if not, which is the predominant pathway operating in 
cells. Additionally, the upstream regulators that activate these pathways in 
response to centriole amplification remain unclear. In order to identify genes 
required for the proliferative arrest in cells with extra centrioles, we performed a 
genome-wide CRISPR/Cas9 knock-out screen. 
 
2.2 Methods 
2.2.1 CRISPR/Cas9 Genome-wide Knock-out Screen 
CRISPR/Cas9 pooled, knockout screens were performed essentially as 
described.15,38,39 RPE1 PLK4Dox cells were infected with a lentivirus containing an 
sgRNA targeting TRIM37 or USP28. The sgRNA sequence targeting TRIM37 
was CTCTAATTTAAATAGCATGG. The sgRNA sequence targeting USP28 was 
ATCAACTCTCCTCCAGTCAT. Infected cells were then selected with 400 μg/mL 
zeocin for 3 weeks and monoclonal knockout lines isolated and validated by 
immunoblotting.  
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The human Brunello CRISPR knockout sgRNA library was purchased 
from Addgene (a gift of David Root and John Doench; #73178) and plasmid DNA 
amplified according to the manufacturer’s instructions. To produce virus, the 
Brunello pooled plasmid library and the lentiviral packaging plasmids psPAX2 
and pMD2.G were co-transfected into 40 x 15 cm culture dishes of HEK293FT 
cells. 6 x 106 HEK293FT cells were seeded into a poly-l-Lysine-coated 15 cm 
culture dish the day before transfection. For each 15 cm dish, the following DNA 
was diluted in 1.2 mL OptiMEM (Thermo Fisher Scientific): 9 μg lentiviral vector, 
12 μg psPAX2, and 3 μg pMD2.G. Separately, 70 μL of 1 μg/μL 25-kD 
polyethylenimine (Sigma-Aldrich) was diluted into 1.2 mL OptiMEM and 
incubated at room temperature for 5 min. After incubation, the DNA and 
polyethylenimine mixtures were combined and incubated at room temperature for 
20 min. During this incubation, the culture media was replaced with 16 mL 
prewarmed DMEM + 1 % FBS. The transfection mixture was then added 
dropwise to the 15 cm dish. Viral particles were harvested at 24, 48 and 72 hr 
after the media change. Media collected from 24, 48 and 72 hr was pooled and 
filtered through a 0.45 μm PVDF syringe filter. The media was then concentrated 
using Amicon Ultra-15 Centrifugal Filter Unit with Ultracel-50 membrane (EMD 
Millipore Corporation cat# UFC905024). The virus was then frozen and stored at 
-80 ºC.  
Cells were transduced with the Brunello library via spinfection as 
previously described.15 To find the optimal virus volumes for achieving an MOI ~ 
0.1, each new batch of virus was titered by spinfecting 3 x 106 cells with several 
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different volumes of virus. Briefly, 3 x 106 cells per well were seeded into a 12 
well plate in growth media supplemented with 10 μg/mL polybrene. Each well 
received a different titrated virus amount (between 5 and 50 μL) along with a no-
transduction control. The plate was centrifuged at 2,000 rpm for 2 hr at room 
temperature. After the spin, media was aspirated, and fresh growth media was 
added. The following day, cells were counted, and each well was split into 
duplicate wells. One well received 3 μg/mL puromycin (Sigma) for 3 days. Cells 
were counted and the percent transduction calculated as the cell count from the 
replicate with puromycin divided by the cell count from the replicate without 
puromycin multiplied by 100. The virus volume yielding a MOI closest to 0.1 was 
chosen for large-scale transductions.  
For the pooled screen, a total of 1 x 108 PLK4Dox; TRIM37-/- or PLK4Dox; 
USP28-/- cells were infected at MOI ∼0.1 and selected with puromycin at 3 μg/mL 
for 3 days. MOI was calculated using a control well infected in parallel following 
the same procedure outlined above. Infected cells were expanded under 
puromycin selection for 5 days and then seeded into 80 x 15 cm dishes with 
250,000 cells per dish. 40 of the dishes received media supplemented with 400 
μg/mL of G418 to maintain selection for the Tet-ON mPLK4 transgene and the 
other 40 dishes received 1 μg/mL of doxycycline and 400 μg/mL of G418. Cells 
were allowed to grow for 21 days without further passaging before being 
harvested for DNA extraction.  
Cell pellets were resuspended in lysis buffer containing 50 mM Tris, 50 
mM EDTA, 1 % SDS, pH 8 and 30 μL of 20 mg/mL proteinase K and incubated 
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at 55 ºC overnight. The next day, 30 μL of 10 mg/mL RNase A was added, and 
the sample was inverted 25 times and incubated at 37 ºC for 30 min. Samples 
were cooled on ice before adding 2 mL of chilled 7.5 M ammonium acetate. 
Samples were then vortexed at high speed for 20 sec and centrifuged at >4000 g 
for 10 min. The supernatants were decanted into new 15 mL conical tubes and 6 
mL of 100 % isopropanol was added. The tubes were inverted 50 times and 
centrifuged at >4000 g for 10 min. The supernatant was discarded and 6 mL of 
freshly prepared 70 % ethanol was added to each tube. The tubes were inverted 
10 times and centrifuged at >4000 g for 1 min. The supernatant was discarded, 
and the pellet was air dried for 30 min. Finally, 200 μL of 1 X TE buffer was 
added, and the tube was incubated at 65 ºC for 1 hr. DNA concentration was 
measured using a Nanodrop.  
The sgRNA library for each sample was amplified and prepared for 
Illumina sequencing using a two-step PCR procedure as previously described.15 
For the first PCR, a region containing the sgRNA cassette was amplified using 




The thermocycling parameters for the first PCR were: 98 °C for 30 sec, 18-24 
cycles of (98 °C for 1 sec, 62 °C for 5 sec, 72 °C for 35 sec), and 72 °C for 1 min. 
1.5 μg of DNA was used in each PCR reaction. Assuming 6.6 pg of DNA per cell, 
~100X representation of the Brunello library required ~53 μg of DNA per sample 
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(36 PCR reactions). The resulting amplicons for each sample were pooled, gel 
purified and used for amplification with barcoded second PCR primers. For each 
sample we performed 12 reactions.  
Primers for the second PCR include both a variable length sequence to 
increase library complexity and an 8 bp barcode for multiplexing of different 
biological samples: 
F2: AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTC 




5 μl of the product from the first PCR reaction were used and the thermocycling 
parameters for the second PCR were: 98 °C for 30 s, 18-24 cycles of (98 °C for 1 
sec, 70 °C for 5 sec, 72 °C for 35 sec). Second PCR products were pooled, gel 
purified and quantified using the Next Library Quantification Kit (NEB). Diluted 
libraries with 5 % PhiX were sequenced with MiSeq (Illumina).  
Sequencing data were processed for sgRNA representation using custom 
scripts. Briefly, sequencing reads were first demultiplexed using the barcodes in 
the forward primer and then trimmed to leave only the 20 bp sgRNA sequences. 
The spacer sequences were then mapped to the spacers of the designed sgRNA 
library using Bowtie.40 For mapping, a maximum of one mismatch was allowed in 
the 20 bp sgRNA sequence. Mapped sgRNA sequences were then quantified by 
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counting the total number of reads. The total numbers of reads for all sgRNAs in 
each sample were normalized.  
The screen was performed two independent times for both PLK4Dox, 
TRIM37-/- and PLK4Dox, USP28-/- cells. We used the MaGeCK scoring algorithm 
(model-based analysis of genome-wide CRISPR-Cas9 knockout) to analyze and 
the rank the genes from the screens.41 We noted that some of the hits from the 
MAGeCK analysis contained sgRNAs with very low representation.42 Among 
these low count hits were many mitochondria and ATP production related genes 
that are likely selected for by the doxycycline treatment. We therefore excluded 
all genes that did not show a   0.005 % representation for at least two sgRNAs 
from the doxycycline treated population from any transduction of either the 
PLK4Dox; TRIM37-/- or PLK4Dox; USP28-/- cell lines. Genes with an FDR cutoff of 
  0.4 were taken forward for further validation.  
2.2.2 Growth Assays 
For competition growth assays, RPE1 PLK4Dox cells constitutively 
expressing EGFP and non-fluorescent RPE1 cells were mixed at a 1:1 ratio and 
seeded into duplicate wells. One well from each pair was treated with 
doxycycline. After 5 days, each well was trypsinized and analyzed on a Guava 
easyCyte flow cytometer to determine the fraction of GFP positive cells. For each 
well, the fraction of GFP positive cells was divided by the GFP negative cells. 
The value obtained from the doxycycline treated well was then divided by that 
obtained in the untreated well to determine the fold change in GFP positive cells.  
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For long-term growth assays, RPE1 PLK4Dox cells were seeded into 
duplicate wells and one well form each pair was treated with 1 μg/mL 
doxycycline. Cell number was counted every 2 days in triplicate using a LUNA-II 
automated cell counter.  
 For clonogenic growth assays, 1 x 103 RPE1 PLK4Dox cells were seeded 
into duplicate 10 cm dishes. One dish was treated with 1 ug/mL doxycycline and 
the other was life untreated. After 10 days, cells were fixed in methanol for 20 
min and stained with crystal violet dye for 20 min at room temperature. Plates 




2.3.1 Centrioles trigger a proliferate arrest in cells 
To study the impact of centrosome amplification on cell proliferation, we 
used hTERT immortalized RPE1 cells that can be induced with doxycycline (dox) 
to overexpress PLK4 (hereafter referred to as PLK4Dox). PLK4Dox cells efficiently 
cluster extra centrosomes during mitosis and undergo a robust P53-dependent 
cell cycle arrest in response to PLK4-induced centrosome amplification.31 To 
determine if the cell cycle arrest that occurs following PLK4 overexpression is 
due to centrosome amplification or an alternative function of PLK4, we created 
dox-inducible PLK4 cells with or without the centriole cartwheel protein SAS6. To 
allow for the continued proliferation of SAS6-/- cells lacking centrioles, we 
performed experiments in a TRIM37 knockout background.16,17 TRIM37 loss 
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allows for the continued growth of acentriolar cells, which would otherwise arrest. 
While TRIM37-knockout RPE1 cells experienced a proliferative arrest after 4 
days of PLK4 overexpression, knockout of SAS6 overcame this proliferative 
arrest (Figure 2.1). This suggests the growth arrest induced by PLK4 
overexpression is due to centrosome amplification and not an alternative function 
of PLK4.  
2.3.2 A CRISPR/Cas9 screen identifies genes required for a proliferative 
arrest following centriole amplification 
To gain insight into how cells respond to extra centrosomes, we designed 
and executed a genome-wide CRISPR-Cas9 knockout screen to identify genes 
required to arrest proliferation following centrosome amplification. We utilized 
PLK4Dox cells carrying a mouse PLK4 transgene that would not be targeted by 
the human PLK4 sgRNAs encoded in the sgRNA library. We also knocked out 
USP28 or TRIM37, which allows for cell proliferation following centrosome loss 
but not following centrosome amplification.15–17 We anticipated two mechanisms 
by which PLK4-overexpressing, USP28 or TRIM37 knockout cells could be 
permitted to proliferate: 1) Loss of genes required for centriole duplication or 
stability, and 2) Loss of genes required to arrest the growth of cells with extra 
centrosomes (Figure 2.2).  
Cas9-expressing PLK4Dox; USP28-/- and PLK4Dox; TRIM37-/- RPE1 cells 
were infected with a genome-wide sgRNA library containing 4 independent 
sgRNAs for every human gene (Figure 2.2). Transduced cells were selected for 7 
days with puromycin, and knockout libraries of cells were treated with dox to 
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induce centrosome amplification and a subsequent cell cycle arrest. After three 
weeks of dox treatment, cells were harvested, and sgRNA abundance was 
analyzed. sgRNAs that provide a growth advantage were expected to be 
enriched in the dox treated population compared with untreated controls. The 
screen was repeated twice for both PLK4Dox; USP28-/- and PLK4Dox; TRIM37-/- 
cells, and the data from the four screens were analyzed together using the 
MAGeCK method for prioritizing genes and pathways41 (Table 2.1, Figure 2.2).  
Of the top 30 hits (FDR  0.4) identified in our screen, 23 were genes that 
encode proteins reported to localize to the centrosome (Table 2.2). From the top 
30 hits of our screen, 14 genes had firmly established roles in centriole 
assembly/stability and were not analyzed further. sgRNAs targeting these genes 
were enriched in our screen because knocking-out these genes prevents 
centriole duplication and leads to centriole loss. TP53 and P21 were both present 
in the remaining 16 genes. Notably, all three components of the PIDDosome 
(PIDD1, CRADD and CASP2) were identified among the top hits from our 
screen, but LATS2 or any other component of the Hippo signaling pathway was 
not.  
Cells expressing sgRNAs targeting each of the remaining 16 genes 
exhibited high levels of centrosome amplification following PLK4 overexpression, 
indicating that knockout of these genes didn’t prevent centrosome amplification. 
We performed competition-based growth assays to validate that knockout of 
these genes enhanced the proliferation of PLK4Dox cells with extra centrioles. As 
expected, sgRNAs targeting CRADD, PIDD1, CASP2, TP53 and P21 increased 
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cell proliferation in response to PLK4 overexpression (Figure 2.2). Furthermore, 
sgRNAs targeting 4 of the remaining 11 genes tested (FOPNL, C2CD3, SCLT1, 
and ANKRD26) increased the proliferation of cells with centrosome amplification 
more than three standard deviations above the mean of control cells. In 
summary, we identified all the known components of the PIDDosome pathway 
along with FOPNL, C2CD3, SCLT1, and ANKRD26 as playing a role in 
suppressing the proliferation of cells with extra centrosomes.  
 
2.4 Discussion 
 Two distinct pathways have been proposed to restrict the proliferation of 
cells with centriole amplification. One is through the activation of the Hippo tumor 
suppressor pathway and the second is through activation of the PIDDosome. 
Both of these responses require P53 stabilization to elicit an arrest. However, the 
mechanism(s) through which these pathways become activated by extra 
centrioles remains poorly understood. 
We show that PLK4 overexpression in an acceptable means of modeling 
centriole amplification. Utilizing CRISPR/Cas9 screening technology, we were 
able to identify genes that limit the proliferation of cells with extra centrosomes 
induced through PLK4 overexpression. All three components of the PIDDosome 
were identified as top hits in our screen, however, LATS2 or any other 
component of the Hippo pathway was not.  
This does not necessarily mean that the Hippo pathway is not involved in 
responding to centriole amplification. LATS2 may not have been identified in out 
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screen for several reasons. First, activation of LATS2 in tetraploid cells may be 
due to an increase in DNA content rather than centriole amplification prese. In 
our screen centriole amplification was driven through overexpression of PLK4, 
which would increase centriole number without a concurrent increase in ploidy. 
Second, loss of LATS2 may only provide cells with a mild growth advantage in 
the presence of extra centrioles. If this is the case, then LATS2-/- may not have 
possessed the fitness required to compete in our screen and come out as a top 
hit. Lastly, knocking-out LATS2 may make cells generally unfit and unable to 
become enriched in our screen. Previous studies of the Hippo pathway in 
tetraploid cells utilized RNAi knock-down of LATS232, which may be better 
tolerated by cells. This is supported by the finding that complete disruption of the 
Lats2 gene in mice results in embryonic lethality.43 
Recent work from multiple labs, however, calls into question the 
involvement of the Hippo pathway in the response to supernumerary 
centrioles.30,44,45 Loss of LATS2 was not able to overcome the growth arrest 
associated with centriole amplification induced through either cytokinesis failure30 
or PLK4 overexpression.44 Additionally, the study that first suggested the Hippo 
pathways involvement in the response to extra centrioles was studying genes 
that, when knocked-down, allow cells to progress through G1 after 
tetraploization. This is not, necessarily a read-out of continued growth. It is 
possible that centriole amplification ultimately leads to an arrest in LATS2-
defficient cells, just during a later cell-cycle. 
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In addition to the previously identified regulators of the response to 
supernumerary centrioles, we also identified four (4) additional genes (FOPNL, 
C2CD3, SCLT1 and ANKRD26) that may function as novel regulators. Cells 
which were knocked-out of each of these genes experienced robust centrosome 
amplification but did not cease proliferation in response. This indicates that they 
these novel regulators are playing a role in the cell-cycle arrest experienced in 




























2.5 Tables for Chapter 2 
Table 2.1: Ranking of positively selected genes from MAGeCK analysis of the 
CRISPR/Cas9 knockout screen with FDR <1 
 
Gene name Score P-value FDR Rank 
C14orf80 1.49E-13 2.59E-07 0.000707 1 
SASS6 2.73E-11 2.59E-07 0.000707 2 
C16orf59 4.32E-10 2.59E-07 0.000707 3 
TUBD1 1.11E-09 2.59E-07 0.000707 4 
HYLS1 2.12E-08 2.59E-07 0.000707 5 
STIL 2.80E-08 2.59E-07 0.000707 6 
RTTN 5.43E-08 2.59E-07 0.000707 7 
PPP1R35 1.32E-07 7.77E-07 0.001856 8 
CEP120 3.84E-07 1.30E-06 0.00275 9 
CRADD 1.22E-06 3.89E-06 0.006188 12 
CENPJ 3.58E-06 1.48E-05 0.017636 16 
PIDD1 6.34E-06 2.67E-05 0.028328 18 
CASP2 1.13E-05 4.74E-05 0.038573 23 
TUBE1 1.28E-05 5.41E-05 0.041386 25 
PIBF1 1.92E-05 7.85E-05 0.048387 31 
CDKN1A 2.61E-05 0.00010179 0.055587 35 
FOPNL 2.72E-05 0.00010697 0.056793 36 
EIF3H 5.02E-05 0.00018778 0.081571 44 
TP53 6.19E-05 0.00022146 0.084653 50 
C2CD3 0.0001139 0.00039189 0.12914 58 
STT3B 0.00016719 0.00054988 0.163441 63 
SPICE1 0.00025879 0.00079957 0.193445 79 
CEP295 0.0006186 0.0017662 0.282715 119 
SCLT1 0.000685 0.0019418 0.295042 125 
ANKRD26 0.00084816 0.0023723 0.328208 137 
CEP152 0.0012426 0.0034912 0.383596 173 
NXT1 0.0014144 0.0039416 0.394459 190 
KIAA0753 0.0014905 0.0041584 0.395305 196 
CEP350 0.0016235 0.0045211 0.397544 217 
CEP44 0.002158 0.0059446 0.417468 267 
ZCCHC14 0.0022678 0.0062554 0.419343 283 
SCAP 0.0052097 0.011918 0.53978 422 
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SIGLEC7 0.0061099 0.013485 0.562136 454 
WBP11 0.011553 0.023021 0.694014 634 
BRD9 0.018535 0.034855 0.779162 855 
UBE2C 0.022183 0.041088 0.811193 966 
CTSE 0.024959 0.04574 0.833387 1049 
C12orf49 0.026166 0.047762 0.837492 1090 
PHF6 0.028021 0.050892 0.848785 1146 
BARHL1 0.030989 0.05585 0.861302 1239 
TUSC5 0.036663 0.065209 0.872086 1419 
MAGEE2 0.03763 0.066802 0.873522 1460 
TRIM65 0.040474 0.071558 0.888109 1540 
OFD1 0.042646 0.075161 0.896163 1603 
NIPAL3 0.042763 0.075373 0.89723 1605 
NGFRAP1 0.042891 0.075579 0.89723 1610 
PHIP 0.043607 0.076736 0.897968 1632 
MED25 0.044044 0.0775 0.899533 1646 
SHROOM2 0.049522 0.081917 0.9135 1713 
LGALSL 0.053747 0.085185 0.927651 1755 
PPP1R8 0.057356 0.087989 0.934293 1800 
KRTAP9-2 0.058157 0.088619 0.936824 1808 
CYSTM1 0.068916 0.097052 0.965117 1922 
ACKR2 0.070998 0.09868 0.970447 1943 
KDELC2 0.071889 0.099387 0.971652 1955 
SRI 0.074113 0.10115 0.976865 1979 
CHD8 0.075397 0.10219 0.978615 1995 
ZC2HC1B 0.077418 0.1038 0.979995 2024 
GJC2 0.082776 0.10804 0.985269 2095 
ZDHHC15 0.083756 0.10881 0.98695 2107 
CCL1 0.083903 0.10894 0.987275 2109 










 Table 2.2: Protein function and localization of the Top30 hits from the 
CRISPR/Cas9 screens 
 
Rank Gene Classification Localization Reference 
1 TEDC1 Centriole assembly Centriole Breslow et al., 2018 
2 SASS6 Centriole assembly Centriole Leidel et al., 2005 
3 TEDC2 Centriole assembly Centriole Breslow et al., 2018 
4 TUBD1 Centriole assembly Centriole Wang et al., 2017 
5 HYLS1 Cilia assembly Centriole 
Dammerman et al., 2009; Hou 
et al., 2020 
6 STIL Centriole assembly Centriole 
Vulprecht et al. 2012; Arquint C, 
2012, Tang et al., 2011 
7 RTTN Centriole assembly Centriole Chen et al, 2017 
8 PPP1R35 Centriole assembly Centriole 
Fong et al. 2018; Sydor et al. 
2018 




response Cytoplasm Fava et al., 2017 










response Cytoplasm Fava et al., 2017 
14 TUBE1 Centriole assembly Centriole Wang et al., 2017 
15 
PIBF1 
(CEP90) Cilia assembly 
Centriole 






response Cytoplasm Holland et al., 2012 
17 
FOPNL 
(FOR20) Cilia assembly 
Centriole 
satellites Sedjaï et al., 2010 
















reticulum   
22 CEP135 Centriole assembly Centriole Yu-Chih et al., 2013 
23 SPICE1 Centriole assembly Centriole Archinti et al., 2010 












appendage This study 
27 CEP152 Centriole assembly Centriole 
Hatch et al., 2010, Cizmecioglu 
et al., 2010 
28 NXT1 Nuclear export Nuclear   
29 KIAA0753 Cilia assembly 
Centriole 
satellites Chevrier et al., 2016 
30 
CEP350 





















2.6 Figures for Chapter 2 
 
 
Figure 2.1: PLK4-induced centriole amplification is required for a cell-cycle 
arrest. A. Growth assay of the indicated cells with and without doxycycline-
inducible overexpression of PLK4. Experiments were performed in wild-type or 
SAS6 monoclonal knockout cells. Data acquired across n = 3 biological 
replicates. Mean ± s.e.m. B. Clonogenic growth assay images of the indicated 











































































Figure 2.2: A genome-wide CRISPR/Cas9 knockout screen identifies regulators 
of the response to centriole amplification. A. Schematic showing the procedure 
for a CRISPR/Cas9 positive selection screen to identify gene knockouts that 
increase the proliferation of cells with extra centrosomes. B. Schematic overview 
of the screen design. C. Top hits that emerged from the screens ranked by 
MaGeCK FDR value. Blue hits are genes required for centriole duplication or 
stability. Green hits are genes predicted to be required to arrest the growth of 
cells with extra centrosomes. D. Hits with known role in centriole duplication or 
stability. E. Candidate hits responsible for arresting the proliferation of cells with 
centrosome amplification. Purple hits correspond to PIDDosome genes. Red hits 
correspond to downstream effectors. Green hits are novel regulators. F. 
Quantification of centrosome number in PLK4Dox cells expressing an sgRNA 
targeting the indicated genes. Experiments were performed in polyclonal 
knockout cells.       G. Graph showing the relative growth of doxycycline treated 
PLK4Dox cells expressing an sgRNA targeting the indicated genes. Each dot 
displays measurements from a single experiment. Experiments were performed 
in polyclonal knockout cells. Data acquired across n ≥ 3 biological replicates. 
Mean ± s.e.m. Data acquired across n ≥ 3 biological replicates. Mean ± s.e.m. 
Data information: Asterisks indicate statistically significant differences between 
measurements (*: P<0.05; **: P<0.01; ***: P<0.001, ****: P<0.0001). Statistics for 
all Figures were calculated using a two-tailed Student’s t-test.  
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Chapter 3: Centriole distal appendages are 
required for the growth arrest in cells following 
centriole amplification 
3.1 Introduction 
 Following mitosis, a cell inherits two centrioles which differ from one 
another in both age and structure.1 One of the centrioles was just built in the 
previous cell-cycle and is, therefore, “younger” than the other centriole which was 
built earlier. The older centriole, referred to as the mature parent or mature 
mother centriole, is decorated with protein structures called distal appendages, 
while the younger centriole lacks such structures. 
 In quiescent cells, the centriole acts as a basal body, which docks at the 
plasma membrane and forms the structural scaffold upon which the primary 
cilium is built. During this process distal appendages on the mature mother 
centriole are important for the membrane docking process and ciliogenesis.5 
Distal appendages may also play a role in cilia gating, selectively allowing 
proteins to enter and exit the ciliary compartment.46 Cilia are necessary for 
proper development and defects in these structures lead to a large range of 
disease, known as ciliopathies.47 The distinction between the mature mother 
centriole with distal appendages and the immature centriole without appendages 
is required to ensure that only a single primary cilium is built. 
 In normal cycling cells, there is only ever one mature mother centriole that 
contains distal appendage structures6, however these structures are dispensable 
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for cell division.48 During mitosis the distal appendages undergo remodeling and 
the outer-most components are temporarily lost.49 Appendages are then fully re-
assembled during G1 of the following cell cycle on the more mature centriole. It 
takes 1.5 cell cycles before a centriole is capable of acquiring distal appendages 
and receiving the title of mature mother.6 
 Interestingly, the core component of the PIDDosome, PIDD1, has been 
shown to localize to the mature mother centriole.30 Knock-out of appendage 
protein ODF2 impaired distal appendage assembly and PIDD1 localization to the 
centriole, indicating that appendages are required for PIDD1 recruitment. 
Furthermore, in cells lacking distal appendages, PIDDosome activation was not 
observed following centriole amplification.30 These data show that PIDD1 
localization to the mature mother centriole is essential for the response to 
supernumerary centrioles. 
We identified nine genes form our CRISPR/Cas9 knock-out screen 
required to prevent proliferation in cells with centriole amplification. Five of these 
genes were previously shown to be involved in arresting cells with extra 
centrioles (P53, CASP2, CRADD, PIDD1 and P21). The remaining four genes 
(FOPNL, C2CD3, SCLT1 and ANKRD26) are novel regulators whose 
involvement in initiating an arrest remains to be discovered. Intriguingly, all four 
of these genes are related to distal appendage formation or cilia assembly. 
FOPNL encodes a protein required for cilia formation; C2CD3, encodes a protein 
required for distal appendage assembly;50  and SCLT1 and ANKRD26 encode 
distal appendage proteins.5,49,51 This suggests that centriole distal appendages 
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3.2.1 Stochastic optical reconstruction microscopy (STORM)  
3.2.1a Immunofluorescence for STORM  
Cells were grown on 25 mm, 1.5 high tolerance coverslips (Warner 
Instruments). Cells were fixed in 1.5 % formaldehyde for 4 min then 
permeabilized in 0.05% Triton for 30 sec. Samples were washed in 1X PBS and 
blocked in IF buffer (1% BSA, 0.05 % Tween-20, in 1 X PBS) for 15 min. Cells 
were incubated with primary antibody diluted in IF buffer at 37 °C for 3 hr. After 
washing in 1X PBS, cells were incubated with secondary antibody diluted IF 
buffer at 37 °C for 3 hr. The following primary antibodies were used: CEP164 
(rabbit, recognizing aa: 1–112, Proteintech, 22227-1-AP, 1:3500), PIDD1 
(mouse, Enzo, ALX-804837C100, 1:500). Conjugated secondary antibodies 
CF647 anti-mouse (Biotium, 20042) and CF568 anti-rabbit (Biotium, 20099) were 
used at 1:800 dilution.  
3.2.1b STORM imaging 
Samples were layered with 100 nm tetra-spectral fluorescent spheres 
(Invitrogen), which served as fiducial markers. Coverslips were mounted in 
Attofluor Cell chambers (Thermofisher) in imaging buffer (25 mM β-
mercaptoethylamine, 0.5 mg/mL glucose oxidase, 67 μg/mL catalase, 10 % 
dextrose, in 100 mM Tris at pH 8.0). 3D STORM imaging was performed on a 
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Nikon N-STORM4.0 system using an Eclipse Ti inverted microscope, Apo TIRF 
100X SA NA 1.49 Plan Apo oil objective, 405, 561,488 and 647 nm excitation 
laser launch and a back-illuminated EMCCD camera (Andor, DU897). The 647 
nm laser line (~150 mW out of the fiber and ~90 mW before the objective lens) 
was used to promote fluorophore blinking. The 405 nm laser was used to 
reactivate fluorophores. The 561 nm laser was used to record the signals of 
fiducial markers. 20,000 to 30,000-time points were acquired at a 50 Hz frame 
rate each 16-20 ms. NIS Elements (Nikon) was used to analyze the data.  
Prior to STORM imaging, the position of CEP164 and PIDD1 was recorded in 
wide-field mode. The original storm Z color coding scheme illustrating the 
calibrated Z range (from red for the signals closer to the coverslip to blue for the 
signals further from the coverslip) is preserved on STORM images, which are 
presented as a projection of the entire 3D volume. The outer and inner diameters 
of distal appendage proteins were determined by measuring the diameters of the 
circles outlining the outer and inner edges of the STORM signal.49 
3.2.2 Fluorescent recovery after photo-bleaching (FRAP) 
 To create the DLD1; PIDD1‐2xmNeonGreen cell line, an sgRNA targeting 
the PIDD1 gene (5′‐cccagagcctgcccaggcct‐3′) was cloned into a pX459 vector 
(#62988; Addgene). To generate the PIDD1 repair vector, we cloned a 2× 
mNeonGreen tag followed by a T2A‐neomycin and a translational stop codon 
into a modified pUC vector. 500 bp 5′ and 500 bp 3′ homology arms were PCR 
amplified from genomic DLD1 DNA and cloned on either side of the central 2′ 
mNeonGreen‐T2A‐Neomycin cassette. DLD1 cells were transiently transfected 
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(X‐tremeGENE HP, Roche) with the pX459 plasmid and repair vector. Selection 
of transfected cells was performed 5 days after transfection with 400 µg/ml G418. 
 DLD1 PIDD1-AausFP1 (PIDD1 overexpressing cells) were generated by 
FLP-IN. PIDD1-AausFP1 was cloned into a pcDNA5 vector and then transfected 
into DLD1 LacZeo cells along with the pOG44 FLP recombinase expression 
vector using XtremeGene HP. Cells were selected with Hygromycin for 14 days. 
Colonies that grew out were pooled together. Cells were treated with doxycycline 
for 48 hrs prior to analysis. 
 FRAP was performed using a Lecia SP8 confocal microscope. Three 
images were collected prior to bleaching. A 3 µm region encompassing the 
PIDD1 foci was bleached with 80% laser intensity and then mages were then 
taken every 10 or 30 sec for 5 or 15 min to measure recovery. 
 
3.3 Results 
3.3.1 PIDD1 localizes to centriole distal appendages 
PIDD1 has been reported to decorate mature centrioles.30 An antibody 
raised against a PIDD1 death domain showed numerous cytoplasmic foci in 
addition to a signal that co-localized with the distal appendage of mature parent 
centrioles. The centriole staining of PIDD1 was lost in PIDD1-/- RPE1 cells while 
the cytosolic foci persisted, suggesting that the cytoplasmic staining is likely to be 
non-specific (Figure 3.1). Consistent with this interpretation, endogenously 
tagged PIDD1-2XmNeonGreen showed a highly specific localization at the 
centriole distal appendage in DLD1 cells and did not label cytosolic structures.  
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Importantly, PIDD1 was observed to localize to the mature mother 
centriole in both cells with normal and amplified centrosome numbers. 3D 
STORM was performed to characterize PIDD1 centriolar localization. This 
revealed that PIDD1 exhibited a nine-fold localization pattern around the top of 
the centriole, consistent with that of distal appendage proteins. PIDD1 had an 
inner and outer diameter of ~349 and ~595 nm, respectively, and its localization 
was most similar to that of ANKRD26,49 which has previously been shown to 
localize at the outer portion of the distal appendage and was also a hit in our 
screen.  
3.3.2 Centriole distal appendages are required for PIDD1 recruitment and 
the cell-cycle arrest in cells with extra centrioles 
We tested whether sgRNAs targeting each of the 9 genes that function to 
suppress the growth of cells with extra centrosomes disrupted the centriole 
recruitment of PIDD1 (Figure 3.2). sgRNA-mediated disruption of CRADD, 
CASP2, TP53, and P21 did not affect the centriole localization of PIDD1. By 
contrast, sgRNAs targeting the novel regulators FOPNL, C2CD3, SCLT1 or 
ANKRD26, dramatically reduced the fraction of cells that recruited PIDD1 to the 
centriole. As mentioned previously, all four of these proteins play a role in distal 
appendage or cilia assembly. 
Previous work has established a hierarchy for centriole distal appendage 
assembly in which C2CD3 is required to recruit CEP83, which recruits SCLT1 
and finally ANKRD26 (Figure 3.2).5,49 C2CD3, SCLT1, and ANKRD26 were 
identified in the top 30 hits of our screens, while CEP83 did not score highly. To 
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examine the role of all of these genes, we established monoclonal PLK4Dox 
knockout cell lines for C2CD3, ANKRD26, SCLT1, and CEP83. Knockout of all 
four genes improved cell proliferation following centrosome amplification (Figure 
3.2) and almost completely abolished the recruitment of PIDD1 to the mature 
parent centriole. These data show that distal appendages are required to recruit 
PIDD1 to mature centrioles and to inhibit cell growth in response to centrosome 
amplification.  
3.3.3 PIDD1 does not dynamically turn over at the centriole 
 PIDD1 localizes to the mature mother centriole irrespective of centriole 
amplification, therefore recruitment to the centriole alone is not sufficient to 
promote PIDDosome activation. We envisioned that PIDD1 may be stably bound 
to distal appendages in cells with normal centriole number, but in cells with extra 
centrioles it might become processed at the centriole and released into the 
cytosol to form an active PIDDosome.  
To investigate if PIDD1 dynamics at the centriole change upon centriole 
amplification, fluorescence recovery after photo-bleaching (FRAP) was 
performed on the centriolar pool of PIDD1 in DLD1 PIDD1-2XmNeonGreen 
endogenously tagged cells. No PIDD1 turnover was observed, regardless of 
centriole number (Figure 3.3), indicating that PIDD1 release is not a likely 
mechanism of PIDDosome activation. This experiment was repeated DLD1 cells 
overexpressing a fluorescently tagged PIDD1 cDNA. In these cells, moderate 
PIDD1 turnover was observed, suggesting that PIDD1 only turns over at the 
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centriole when overexpressed to non-physiological levels. This may explain why 
the centriolar pool of PIDD1 was previously reported to exhibit high turnover.45 
 
3.4 Discussion 
Centriole distal appendages are known to function in basal body docking 
at the centriole during the process of ciliogenesis in quiescent cells5, however the 
role that distal appendages play in cycling cells remains unclear. It is largely 
believed that distal appendages are unnecessary in cycling cells, since these 
structures are not required for successful cell division.48 
The requirement of centriole distal appendages for PIDDosome activation 
following centrosome amplification suggests that these structures are essential 
for initiating the proliferative arrest and are being actively monitored in cells. This 
is consistent with a previously model in which an increase in the number of 
mature parent centrioles was proposed to be the cue that triggers PIDDosome 
activation.30 We show that PIDD1 localizes to that distal appendages in cells with 
normal centriole number as well as in cells with centriole amplification. This 
raises the question, how does the PIDDosome become specifically activated in 
cells with supernumerary mature mother centrioles? 
Based on our FRAP data, it is evident that PIDD1 is not being processed 
at the centriole and released into the cytosol to form an active PIDDosome. It is 
possible, however, that cells with extra mature mother centrioles cluster these 
structures in order to; 1.) increase the local PIDD1 concentration enough to reach 
and activation threshold, 2.) arrange PIDD1 molecules in the correct orientation 
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to form an active PIDDosome complex, or 3.) facilitate a conformational change 
in PIDD1 which leads to its activation. Consistent with this idea, supernumerary 
centrioles have been shown to cluster in both interphase and mitotic cells21, and 
PIDD1 in these centrioles clusters are arrange in close proximity to one 
another.45 
The active PIDDosome complex has been shown to be composed of five 
PIDD1 and seven CRADD proteins, which interact with each other via their death 
domains.52 We illustrate that PIDD1 interacts with the distal appendages and that 
its localization at the mature mother centriole exhibits a 9-fold symmetrical 
pattern. In support of the clustering model, it is unlikely that at a single centriole 
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Figure 3.1: PIDD1 localizes to the distal appendages of the mature mother 
centriole. A. Representative images of wild‐type and PIDD1−/− PLK4Dox RPE1 
cells immunostained with the indicated antibodies. Scale bar = 5 µm. B. 
Representative images of PLK4Dox PIDD1‐mNeonGreen DLD1 cells treated with 
and without doxycycline for 2 days and immunostained with the indicated 
antibodies. Scale bar = 5 µm. C. Top, widefield image showing the localization of 
CEP164 and PIDD1 at the mature- mother centriole. Bottom: Representative 3D 
STORM image of the same centriole showing PIDD1 localization. STORM image 
colors correspond to the Z-depth with red being the closest to the coverslip and 
blue being the most distant. D. Inner and outer diameter measurements for distal 
appendage proteins and PIDD1. Measurements in the shaded region were 
previously reported in (Bowler et al., 2019). Data displayed as box and whisker 
plots, where the box represents the upper and lower quartile and the whiskers 
represent the s.d. Scale bars: 1 μm for all wide-field images of centrioles and 500 
nm for STORM images. Data acquired across n ≥6 cells. E. 3D STORM image of 
PIDD1 at the mature mother centriole. The overlaid mask represents the inner 


















Figure 3.2: Distal appendages are required for PIDD1 recruitment and 
PIDDosome activation. A. Quantification of the fraction of cells with PIDD1 
localized to the mature mother centriole in PLK4Dox cells expressing an sgRNA 
targeting the indicated genes. A dot displays measurements from each 
experiment. Experiments were performed in PLK4Dox polyclonal knockout cells. 
Data acquired across n = 3 biological replicates. Mean ± s.e.m. B. Schematic 
depicting the hierarchy of recruitment of distal appendage proteins. C. Graph 
showing the relative growth of doxycycline treated PLK4Dox cells that were 
knocked out for the indicated genes. Each dot displays measurements from a 
single experiment. Experiments were performed in PLK4Dox monoclonal knockout 
cells. Data acquired across n ≥ 3 biological replicates. Mean ± s.e.m. D. 
Quantification of the fraction of cells with PIDD1 localized at the mature mother 
centriole. Experiments were performed in PLK4Dox monoclonal knockout cells. 
Data acquired across n = 3 biological replicates. Mean ± s.e.m. Data information: 
Asterisks indicate statistically significant differences between measurements (**: 
P<0.01; ***: P<0.001, ****: P<0.0001). Statistics for all Figures were calculated 








Figure 3.3 PIDD1 stably interacts with centriole distal appendages. A. 
Representative image of PIDD1-2XmNeonGreen in endogenously tagged DLD1 
cells. Scale bar = 5 µm. B. Quantification of fluorescence recovery after 
photobleaching. Data acquired across n ≥ 15 cells per condition. Mean + s.e.m. 
C. Representative images of the PIDD1-2XmNeonGreen foci in cells with and 
without centriole amplification before bleaching, immediately after bleaching and 
at selected points during the recovery period. D. Top: Quantification of 
fluorescence recovery after photobleaching. Data acquired across n ≥ 14 cells 
per condition. Mean + s.e.m. Bottom: Representative images of the PIDD1-
AausFP1 foci in cells before bleaching, immediately after bleaching and at 
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Chapter 4: ANKRD26 is required for PIDDosome 
activation following centriole amplification 
4.1 Introduction 
 Ankyrin repeat domain 26 (ANKRD26) is a recently identified distal 
appendage protein that localizes to the periphery of the distal appendages.49 
Prior to its identification at distal appendages and its characterization in the 
response to supernumerary centrioles44,45, little was known about the function of 
ANKRD26. Mutations in ANKRD26 have been identified in patients with 
thrombocytopenia53, which is a condition where an abnormally low number of 
platelets are produced. Most of the mutations in ANKRD26 identified in families 
with thrombocytopenia occur in the 5’ untranslated region (UTR).54 These 
mutations in the 5’ UTR of ANKRD26 silence its transcriptional repression and 
lead to constitutive expression in megakaryocytes (platelet producing cells).53 
 Disruption of the Ankrd26 gene in mice has been shown to cause 
hyperphagia and obesity.55 This phenotype is cause by a defect in primary cilia 
formation in the central nervous system, leading to dysregulation of appetite and 
energy homeostasis.56 However, whether this phenotype is related to the role of 
ANKRD26 at the centriole distal appendage or its function in response to extra 




4.2.1 Cytokinesis failure assay 
To look at the effects of cytokinesis failure, PLK4Dox cells were seeded in 
duplicate wells. One well was treated with 10 μg/mL cytochalasin B (Sigma-
Aldrich) and the other well was treated with DMSO for 24 hrs. Cells were then 
washed with media 3 times and then fresh media was added to cells 
supplemented with 10 μM EdU (Invitrogen) and 10 μM Dimethylenastron (DMN) 
(Sigma-Aldrich). Cells were incubated for 24 hrs. Cells were then collected and 
fixed with 100% ethanol at -20 ºC for at least 1 hr. Each sample was washed with 
PBS then stained with a Click-iT reaction for 30 min in the dark. The Click-iT 
reaction was prepared following manufacturer’s protocol (Invitrogen). Samples 
were washed and stained with a 25 μg/mL propidium iodide solution 
supplemented with RNase A (Sigma-Aldrich) for 30 min in the dark. Samples 
were analyzed on a BD FACSCalibur flow cytometer to determine DNA content 
and EdU incorporation. The percent of EdU-positive cells with a DNA content of 
greater than 4N was determined for each sample. The DMSO-treated sample 
was subtracted from the cytochalasin B- treated sample for each cell line.  
4.2.2 Griseofulvin assay 
PLK4Dox cells were grown on 18-mm glass coverslips and treated with 
griseofulvin (Sigma-Aldrich, 25 µM) for 24 hr. Cells were then fixed in 100 % -20 
C methanol for 10 min and processed for immunofluorescence staining. 
Anaphase cells were imaged, and spindle morphology scored.  
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4.2.3 Cilia assembly 
hTERT RPE1 cells were grown to confluency on 18-mm glass coverslips 
and then placed in serum-free media (DMEM:F12 50:50 medium supplemented 
with 0.348% sodium bicarbonate, 100 U/ml penicillin, 100 U/ml streptomycin, and 
2 mM L-glutamine) for 2 days. Prior to fixation, cells were washed with 1 X PBS 
and incubated in microtubule stabilization buffer (30% glycerol, 100 mM PIPES, 1 
mM EGTA, 1 mM MgSO4) for 30 sec. Cells were then washed with PBS and 
processed for immunofluorescence staining.  
4.2.4 Immunoblotting 
Immunoblotting and immunofluorescence were performed as previously 
described.57 For immunoblot analysis, protein samples were separated by SDS-
PAGE, transferred onto nitrocellulose membranes with a Trans-Blot Turbo 
Transfer System (BioRad) or by overnight wet-transfer (25 V for 16 hrs in the 
cold room). For semi-dry transfer, buffer containing 25.3 mM Tris Base, 0.19M 
glycine and 20 % methanol. For wet-transfer, 25 mM Tris Base, 190 mM glycine, 
0.1 % (w/v) SDS and 20 % methanol. Blots were probed with the following 
antibodies: alpha-tubulin (rat, Y1/2, Invitrogen, MA180017, 1:1000), ANKRD26 
(rabbit, GeneTex, GTX128255, 1:1000), Caspase 2 (rat, 11B4, Millipore Sigma, 
MAB3507, 1:1000), and p21WAF1 (mouse, Ab-1, CalBiochem, OP64, 1:100). 
Blots were blocked with 5% milk in TBST and washed with TBST. Images were 
captured on a Syngene G:Box. 
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4.2.5 Co-immunoprecipitation 
Co-immunoprecipitation was performed as previously described.57 2 x 106 
HEK293FT cells were seeded into 10 cm2 dishes and 24 hours later were 
transfected with 3 μg of plasmid DNA. 48 hours later, transfected cells were lysed 
in lysis buffer (10 mM Tris pH 7.5, 0.1% Triton X-100, 250 mM NaCl, 1 mM 
EDTA, 50 mM NaF, 50 mM β-glycerophosphate, 1 mM DTT, 500 nM microcystin, 
1 mM PMSF and EDTA-free protease inhibitor tablet (Roche)), sonicated and 
soluble extracts prepared. The supernatant was incubated with beads coupled to 
GFP-binding protein.58 Beads were washed 3 times in lysis buffer, and 
immunopurified protein was analyzed by immunoblot.  
4.2.6 Immunofluorescence 
For immunofluorescence, cells were grown on 18‐mm glass coverslips 
and fixed in 100 % −20 °C methanol for 10 min. Cells were blocked in 2.5 % 
FBS, 200 mM glycine, and 0.1 % Triton X‐100 in PBS for 1 h. Antibody 
incubations were conducted in the blocking solution for 1 h. DNA was detected 
using DAPI, and cells were mounted in Prolong Antifade (Invitrogen). Staining 
was performed with the following primary antibodies: Centrin (rabbit, directly 
conjugated,59 1:1,000), ANKRD26 (rabbit, GeneTex, GTX128255, 1:1000), 
SCLT1 (rat,5 1:250), CEP83 (rabbit, Sigma‐Aldrich, HPA038161, 1:200), CEP89 
(rat,5 1:500), Polyglutamylation (mouse, GT335, AdipoGen, AG‐20B‐0020‐C100), 
FOPNL/FOR20 (rat,60 1:500), C2CD3 (rabbit, Atlas Antibodies, HPA038552, 
1:500), and CEP164 (rabbit, Millipore Sigma, AEB2621, 1:1,000). Secondary 
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donkey antibodies were conjugated to Alexa Fluor® 488, 555, or 650 (Life 
Technologies). 
Immunofluorescence images were collected using a Deltavision Elite 
system (GE Healthcare) controlling a Scientific CMOS camera (pco.edge 5.5). 
Acquisition parameters were controlled by SoftWoRx suite (GE Healthcare). 
Images were collected at room temperature using an Olympus 60× 1.42 NA or 
Olympus 100× 1.4 NA oil objective at 0.2 μm z‐sections and subsequently 
deconvolved in SoftWoRx suite. Images were acquired using Applied Precision 
immersion oil (N = 1.516). 
4.2.7 Edu Incorporation 
PLK4Dox cells were seeded in duplicate wells and one was treated with 
one of the following drugs: doxorubicin (Sigma‐Aldrich, 50 ng/µL) for 2 days, 
reversine (Sigma‐Aldrich, 500 nM) for 2 days, centrinone (Tocris, 125 nM) for 
5 days or H2O2 (30% w/w Sigma-Aldrich, 150 nM) for 2 h followed by an 
overnight incubation in fresh media. Both the treated and untreated wells were 
seeded onto 18‐mm glass coverslips and incubated in media supplemented with 
10 µM EdU for 24 h. Cells were then fixed in 100 % −20 °C methanol for 10 min, 
washed with PBST and a Click‐iT reaction was performed for 30 min in the dark 
to label EdU. Each coverslip was incubated with 197.2 µl 1× PBS, 2.5 µl 100 mM 
CuSO4, 50 µl 500 mM Ascorbic Acid (prepared fresh), and 0.3 µl 125 µM Azide‐
fluor 488 (Millipore Sigma). After 30 min, cells were rinsed with PBS, DAPI 





4.3.1 ANKRD26 loss allows for the long-term growth of cells with centriole 
amplification 
In accord with its localization to the peripheral region of the distal 
appendage blade, ANKRD26 localization at mature centrioles was abolished in 
C2CD3-/-, SCLT1-/-, and CEP83-/- cells. Moreover, knocking-out FOPNL also 
prevented ANKRD26 and PIDD1 recruitment to the centriole, suggesting that 
while not a distal appendage protein perse, FOPNL plays a role in the assembly 
of the centriole distal appendages. Conversely, ANKRD26-/- cells had a normal 
distal appendage localization of CEP83, SCLT1, CEP89, and CEP164. Centriole 
distal appendages are known to play a role in membrane docking of the basal 
body and ciliogenesis. These functions were not disrupted in ANKRD26-/- cells, 
which formed cilia upon serum starvation at a frequency comparable to wild-type 
RPE1 cells (Figure 4.1). These data suggest that the distal appendage remains 
mostly intact in cells lacking ANKRD26.  
Knockout of ANKRD26 allowed for the long-term growth of cells with extra 
centrioles generated by overexpression of PLK4 (Figure 4.1). To further test if 
ANKRD26 suppresses the proliferation of cells with extra centrioles, we used two 
additional methods to drive the formation of excessive centrioles that did not 
require overexpression of PLK4. First, overexpression of the centriole structural 
component SAS6 led to centrosome amplification that reduced cell proliferation.31 
This decrease in proliferation was alleviated by knockout of ANKRD26. Second, 
we treated cells with cytochalasin B to induce cytokinesis failure and tested the 
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ability of ANKRD26, PIDD1 and CASP2 to arrest the proliferation of tetraploid 
cells that have twice the normal centrosome content. Knockout of ANKRD26, 
PIDD1 or CASP2 increased the fraction of cycling tetraploid cells, indicating that 
all three of these genes act to restrict the proliferation of newly created tetraploid 
cells. We note that the relative increase in growth following loss of ANKRD26 in 
tetraploid cells was more modest than what was observed in cells with extra 
centrosomes generated by PLK4 overexpression. This may reflect the shorter 
duration of the growth assays performed in tetraploid cells (2 days) compared to 
those carried out in PLK4Dox cells (5 days). Alternatively, tetraploid cells may 
activate other ANKRD26-independent pathways that restrict cell proliferation.32  
Importantly, ANKRD26 was not required for normal centriole duplication, 
as ANKRD26-/- cells experienced robust centriole amplification when PLK4 was 
overexpressed. To test if the extra centrosomes in ANKRD26-/- cells could act as 
microtubule organizing centers (MTOCs), we treated PLK4Dox cells with dox for 
two days and then added the centrosome de-clustering agent griseofulvin.61 As 
expected, extra centrosomes in both wild-type and ANKRD26-/- cells nucleated 
microtubules that led to multi-polar divisions in the presence of griseofulvin. We 
conclude that ANKRD26 is required to restrict the proliferation of cells following 
centrosome amplification but is not required for cilia assembly, centriole 
duplication, or PCM recruitment.  
4.3.2 ANKRD26 links extra centrosomes to PIDDosome activation 
To test the effect of ANKRD26 knockout on PIDDosome activation, we 
monitored the loss of pro-CASP2 and the upregulation of P21 upon centrosome 
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amplification. As expected30, the levels of pro-CASP2 decreased, and P21 
increased in PLK4Dox cells in a time-dependent manner following dox addition 
(Figure 4.2). Knockout of TP53 prevented P21 upregulation but did not affect pro-
CASP2 processing following centrosome amplification, which is consistent with 
its position downstream of CASP2 in the pathway. By contrast, knockout of 
ANKRD26 suppressed both CASP2 activation and P21 upregulation in cells with 
extra centrosomes. These data show ANKRD26 acts as an upstream activator of 
the PIDDosome and CASP2 in cells with supernumerary centrosomes.  
CASP2 is activated in response to several different upstream signals.62 To 
investigate if the loss of ANKRD26 globally prevents CASP2 activation, we tested 
the ability of ANKRD26-/- and TP53-/- cells to activate CASP2 following DNA 
damage induced by etoposide. While the loss P53 prevented P21 expression 
downstream of CASP2 activation, knockout of ANKRD26 did not alter CASP2 
activation or P21 induction in cells that experienced DNA damage (Figure 4.2). 
This suggests that ANKRD26 is required to activate CASP2 in cells with extra 
centrosomes but is not required for CASP2 function perse. Notably, CASP2 
processing still occurred in PIDD1-/- cells treated with etoposide, suggesting that 
etoposide-induced CASP2 activation is independent of the PIDDosome.  
We next investigated if ANKRD26-/- cells were defective in other P53-
dependent response pathways. Knockout of ANKRD26-/- did not affect the ability 
of cells to arrest following DNA damage, centrosome loss, and chromosome 
segregation errors. Moreover, ANKRD26-/- cells underwent H2O2-induced arrest 
at similar levels to control cells. By contrast, TP53-/- cells exhibited enhanced 
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growth in all of these conditions. Since upstream components of the DNA 
damage and senescence pathways did not emerge as hits in our screen, we 
conclude that ANKRD26-mediated activation of P53 only occurs following 
centriole amplification and is functionally distinct from the DNA damage and 
senescence response pathways.  
4.3.3 The ANKRD26 coiled-coil region interacts with the UPA domain of 
PIDD1 
To determine which region of ANKRD26 is required to recruit PIDD1 to 
centriole distal appendages, we expressed deletion mutants of mCherry-
ANKRD26 in ANKRD26-/- cells and monitored PIDD1 recruitment to the centriole. 
The deletion of the ANKRD26 N- terminus (amino acids 1-344) led to a partial 
reduction in the centriole recruitment of ANKRD26 and PIDD1. In contrast, 
deletion of the ANKRD26 C- terminus (amino acids 1231-1710) prevented the 
centriole localization of both proteins (Figure 4.3). This suggests that the N and 
C-terminal region of ANKRD26 both play a role in its own centriole recruitment.  
The deletion of the ANKRD26 M1 region (amino acids 345-849) had no 
impact on the centriole recruitment of ANKRD26, but partly compromised the 
centriole localization of PIDD1. Notably, deletion of ANKRD26 M2 (amino acids 
850-1320) localized to the centriole, but completely failed in the recruitment of 
PIDD1 (Figure 4.3). These data indicate that the 850-1320 amino acid region of 
ANKRD26 is required for the recruitment of PIDD1 to the centriole distal 
appendage.  
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The 850-1320 amino acid region of ANKRD26 contains a conserved 
coiled-coil region (CCDC144C, amino acids 913-1216). To establish if this coiled-
coil region is responsible for binding to PIDD1, we overexpressed in cells with a 
normal centrosome content mCherry-ANKRD26 coiled-coil (mCherry-
ANKRD26CC) and wild-type PIDD1- FLAG. Purified mCherry-ANKRD26CC 
associated with PIDD1-FLAG, showing that the coiled-coil region of ANKRD26 is 
sufficient for PIDD1 binding.  
Full-length PIDD1 is processed into three fragments: an N-terminal piece 
called PIDD1-N and two C-terminal fragments, PIDD1-C and PIDD1-CC, 
respectively.36,63 Cleavage occurs at S446 and S588 through an autoproteolytic 
process similar to the mechanism described by self-cleaving protein segments 
such as inteins. Full-length PIDD1 is rapidly processed in cells to form PIDD1-C, 
while the second cleavage event that forms the PIDD1-CC fragment is stimulated 
by specific inputs.63 To define the region of PIDD1 that interacts with ANKRD26, 
we expressed in cells mCherry- ANKRD26CC along with FLAG-tagged PIDD1-N, 
PIDD1-C, and PIDD1-CC. mCherry- ANKRD26CC interacted with the PIDD1-C 
and PIDD1-CC fragments but failed to bind PIDD1-N (Figure 4.3). Importantly, 
ANKRD26CC did not bind to PIDD1 lacking the CC fragment (PIDD1 CC), 
demonstrating that the CC fragment of PIDD1 is both necessary and sufficient for 
ANKRD26 binding.  
The PIDD1-CC region contains a UPA domain of unknown function64 and 
a death domain (DD) that binds to CRADD to form the PIDDosome.52 To 
establish which of these domains are responsible for associating with ANKRD26, 
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we tested the ability of PIDD1 mutants lacking the UPA domain or DD to bind to 
ANKRD26CC. ANKRD26CC robustly interacted with PIDD1 lacking the DD 
(PIDD1DD), but only weakly associated with PIDD1 deleted of the UPA domain 
(PIDD1UPA). This suggests that the coiled-coil region of ANKRD26 
predominantly associates with the PIDD1 UPA domain.  
Additionally, a non-cleavable mutant of PIDD1 retained its ability to 
interact with ANKRD26CC, arguing that PIDD1 cleavage is not required to bind to 
ANKRD26. In fact, ANKRD26CC preferentially binds to unprocessed, full-length 
PIDD1.  
4.3.4 ANKRD26-mediated recruitment of PIDD1 to the distal appendage is 
required for PIDDosome activation 
To test the role of ANKRD26-mediated recruitment of PIDD1 in activating 
the PIDDosome, we expressed a mCherry-ANKRD26 or mCherry-ANKRD26CC 
transgene in ANKRD26-/- PLK4Dox cells. Expression of a wild-type mCherry-
ANKRD26 transgene was able to rescue PIDD1 recruitment to the mature parent 
centrioles. Furthermore, wild-type mCherry-ANKRD26 promoted PIDDosome 
activation and suppressed the proliferation of cells with extra centrioles. By 
contrast, although the mCherry-ANKRD26CC mutant localized to the centriole, 
it could not recruit PIDD1 to the distal appendage. Importantly, the mCherry-
ANKRD26CC mutant did not restrict proliferation in cells with extra centrioles, 
nor did it induce PIDDosome activation. This suggests that ANKRD26-mediated 
recruitment of PIDD1 to the distal appendage is required for PIDDosome 
activation and growth arrest following centriole amplification.  
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4.3.5 A recurrent cancer mutation disrupts the ability of ANKRD26 to arrest 
the proliferation of cells with extra centrioles  
We investigated whether defects in ANKRD26-mediated PIDDosome 
activation occur in human cancers. Interestingly, a single nucleotide deletion in 
ANKRD26 was found in 20 independent tumors from the colon, stomach, uterus, 
and brain (Figure 4.4).42 This one base pair deletion resulted in a K1234N 
mutation and a premature translational stop that truncated ANKRD26 just after 
the CC domain that interacts with PIDD1. The striking recurrence of the same 
mutation suggests that the K1234Nfs*19 alteration is selected for in these 
cancers. To test the impact of this mutation on ANKRD26-mediated PIDDosome 
activation, we expressed a mCherry- ANKRD26 K1234Nfs*19 transgene in 
ANKRD26-/- PLK4Dox cells.  
Similar to what was observed following the deletion of the ANKRD26 C-
terminus (amino acids 1231-1710), the mCherry-ANKRD26 K1234Nfs*19 mutant 
localized inefficiently to the centriole and was defective in recruiting PIDD1 to the 
distal appendage (Figure 4.4). This mutant also failed to promote PIDDosome 
activation and restrict the proliferation of cells with extra centrosomes. This 
suggests that the K1234Nfs*19 mutation disrupts the ability of ANKRD26 to 
localize to the centriole and trigger PIDD1 activation following centrosome 
amplification.  
P53 functions downstream of ANKRD26 to arrest the growth of cells with 
extra centrosomes. Given that P53 loss of function frequently occurs in human 
tumors and would be expected to overcome the requirement for ANKRD26-
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disrupting mutations, we analyzed the fraction of ANKRD26 K1234Nfs*19 tumors 
that also showed oncogenic TP53 alterations. Of the 20 tumors containing 
K1234N mutations, 15 % also contained an oncogenic TP53 alteration, and an 
additional 15 % have a TP53 variant of unknown significance (Table 4.1). This 
fraction is lower than the overall frequency of TP53 alterations observed for each 
tumor type subtype. However, since the numbers of tumors analyzed are small, 
no definitive conclusions can be drawn at this stage.  
 
4.4 Discussion 
 ANKRD26 is required for PIDD1 recruitment to the centriole and 
PIDDosome activation following centriole amplification induced either by PLK4 
overexpression or cytokinesis failure. Loss of ANKRD26 prevented downstream 
stabilization of P53 in cells with extra centrioles, but other cellular stress 
responses remained intact. These data indicate that ANKRD26 is uniquely 
involved in initiating a P53-dependent arrest in response to centriole 
amplification. 
Loss of ANKRD26 allows for the continued proliferation of genetically 
unstable cells with centriole amplification. This raises the question of whether 
mutations in ANKRD26 are selected for during the process of tumorigenesis. We 
predict that loss of ANKRD26 would offer no fitness advantage in tumor cells that 
lack P53 functionality, perhaps explaining why ANKRD26 mutations are not 
commonly observed in human cancers. Nevertheless, a query of the cBioPortal 
database did reveal a recurrent frameshift mutation in ANKRD26 (K1234Nfs*19) 
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observed in multiple stomach, brain, uterine, and colon tumors.42 This mutation 
leads to the expression of a truncated form of ANKRD26 that fails to recruit 
PIDD1 to the centriole and activate the PIDDosome in response to centriole 
amplification. This suggests that loss of ANKRD26‐mediated PIDD1 signaling is 
selected for in some human tumors. It is plausible that the K1234Nfs*19 
ANKRD26 mutation enables the continued propagation of tumor cells with extra 
centrioles. It would be interesting to examine if selection for this mutation co‐
occurs with centriole amplification in cancer cells. 
In addition to a possible role of ANKRD26 mutations in tumorigenesis, 
mutations in the 5' UTR of the ANKRD26 gene cause an autosomal‐dominant 
form of thrombocytopenia due to reduced blood platelet production by 
megakaryocytes.65,66 During their maturation, megakaryocytes undergo several 
rounds of endomitosis (mitosis without cytokinesis) to produce large polyploid 
cells with extra centrosomes.67 Thrombocytopenia‐associated mutations 
in ANKRD26 lead to the persistent expression of ANKRD26 during the late 
stages of megakaryocyte development, and, consequently, megakaryocytes from 
these patients exhibit reductions in cell ploidy.53 Based on our observations 
regarding the role of ANKRD26 in responding to centriole amplification, it is 
tempting to speculate that the reduction in megakaryocyte ploidy in these 
patients arises due to ANKRD26‐mediated activation of the PIDDosome in 
megakaryocytes with extra centrioles. Patients with mutations in the 5′ UTR 
of ANKRD26 also exhibit an increased incidence of myeloid malignancies65,66,68, 
and N‐terminal truncating mutations in ANKRD26 have been identified in 
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sporadic, adult‐onset AML cases.54 How these ANKRD26 mutations lead to an 





















4.5 Tables for Chapter 4 
Table 4.1: TP53 mutational status of tumors containing the ANKRD26 
K1234Nfs*19 mutation 
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Figure 4.1 ANKRD26 is uniquely involved in the response to centriole 
amplification. A. Quantification of the fraction of cells with ANKRD26 localized at 
the mature mother centriole. Experiments were performed in PLK4Dox monoclonal 
knockout cells. Data acquired across n = 3 biological replicates. Mean ± s.e.m.  
B-D. Representative images of WT or ANKRD26−/− cells immunostained with the 
indicated antibodies. Scale bar = 5 µm. E. Quantification of the fraction 
of WT or ANKRD26−/− hTERT RPE1 cells with cilia. Each dot displays 
measurements from a single experiment. Data acquired across n = 5 biological 
replicates. Mean ± s.e.m. F. Growth assay of the indicated cells with and without 
doxycycline‐inducible overexpression of PLK4. Experiments were performed in 
PLK4Dox monoclonal knockout cells. Data acquired across n = 3 biological 
replicates. Mean ± s.e.m. G. Graph showing the relative growth of doxycycline‐
treated SAS6Dox cells that were knocked out for the indicated genes. Experiments 
were performed in SAS6Dox monoclonal knockout cells. Each dot displays 
measurements from a single experiment. Data acquired across n = 3 biological 
replicates. Mean ± s.e.m. H. Quantification of the fold change in cycling cells with 
a DNA content > 4N following cytokinesis failure. Experiments were performed in 
PLK4Dox monoclonal knockout cells. Each dot displays measurements from a 
single experiment. Data acquired across n = 4 biological replicates. 
Mean ± s.e.m. I. Quantification of centrosome number in PLK4Dox cells 
expressing an sgRNA targeting the indicated genes. Experiments were 
performed in PLK4Dox monoclonal knockout cells. Data acquired across n = 3 
biological replicates. Mean ± s.e.m. J. Quantification of the fraction of cells with 
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the indicated mitotic spindle orientation following treatment with the centrosome 
declustering agent griseofulvin. Experiments were performed in monoclonal 
PLK4Dox knockout cells. Data acquired across n = 3 biological replicates. 
Mean ± s.e.m. K. Representative images of PLK4Dox cells treated with and 
without doxycycline for two days then treated with griseofulvin for 24 h. 
Experiments were performed in monoclonal PLK4Dox knockout cells. Cells were 
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Figure 4.2 ANKRD26 is required for PIDDosome activation in cells with extra 
centrioles. A. Western blot showing expression of pro‐CASP2 and P21 following 
treatment with dox for the specified number of days. Experiments were 
performed in PLK4Dox monoclonal knockout cells. B. Quantification of pro‐CASP2 
levels following treatment with dox for the specified number of days. Experiments 
were performed in PLK4Dox monoclonal knockout cells. Each dot displays 
measurements from a single experiment. Data acquired across n = 6 biological 
replicates. Mean ± s.e.m. C. Western blot showing expression of pro‐CASP2 and 
P21 following treatment with etoposide. Experiments were performed in 
PLK4Dox cells knocked out for the indicated genes. D. Quantification of the 
fraction of proliferating cells following treatment with the indicated 
drugs/reagents. Experiments were performed in monoclonal PLK4Dox knockout 






























































































































































































































































































































































































Figure 4.3 The coiled-coil domain of ANKRD26 interacts with the UPA domain of 
PIDD1 to recruit it to the centriole. A. Schematic representation of wild‐type 
ANKRD26 and various mutants. B. Quantification of the fraction of cells with 
ANKRD26 localized to the mature mother centriole in monoclonal ANKRD26−/− 
PLK4Dox cells expressing the indicated mCherry‐ANKRD26 transgene. Each dot 
displays measurements from a single experiment. Data acquired across n ≥ 3 
biological replicates. Mean ± s.e.m. C. Quantification of the fraction of cells with 
PIDD1 localized to the mature mother centriole in 
monoclonal ANKRD26−/− PLK4Dox cells expressing the indicated mCherry‐
ANKRD26 transgene. Each dot displays measurements from a single 
experiment. Data acquired across n = 3 biological replicates. Mean ± s.e.m. D. 
Top: schematic representation of PIDD1 and its cleavage products. Bottom: 
HEK293FT cells were transfected with the indicated constructs, subjected to co‐
immunoprecipitation with mCherry binder beads and immunoblotted with the 
indicated antibodies. E. HEK293FT cells were transfected with the indicated 
constructs, subjected to co‐immunoprecipitation with mCherry binder beads and 

















Figure 4.4 Full-length ANKRD26 is able to rescue PIDD1 recruitment and 
PIDDosome activation in ANKRD26-/- cells. A. Quantification of the fraction of 
cells with ANKRD26 (left) and PIDD1 (right) localized to the mature mother 
centriole in monoclonal ANKRD26−/− PLK4Dox cells expressing the indicated 
transgenes. Each dot displays measurements from a single experiment. Data 
acquired across n = 3 biological replicates. Mean ± s.e.m. B. Graph showing the 
relative growth of doxycycline‐treated, monoclonal ANKRD26−/− PLK4Dox cells 
expressing the indicated ANKRD26 transgenes. Each dot displays 
measurements from a single experiment. Data acquired across n = 3 biological 
replicates. Mean ± s.e.m. C. Western blot showing expression of pro‐CASP2 and 
P21 following treatment with dox for 4 days. Experiments were performed in 
monoclonal ANKRD26−/− PLK4Dox cells expressing the indicated transgenes. D. 
Western blot showing the expression of ANKRD26. Experiments were performed 
in monoclonal ANKRD26−/− PLK4Dox cells expressing the indicated ANKRD26 
transgenes. E. Schematic showing the location of the 533 mutations 
in ANKRD26 in human tumors. Black represents truncating mutations; green 
represents missense mutations; purple represents inframe mutations. The 
K1234Nfs*19 mutation is shown in red. Data from curated set of non‐redundant 
studies in cBioPortal.42  
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Chapter 5: Designing a knock-out mouse to study 
the effects of Ankrd26 loss in vivo 
5.1 Introduction 
 Partial inactivation of Ankrd26 in mice has been achieved by insertion of a 
β-galactosidase gene into the Ankrd26 locus using the gene trap technique.55 
This insertion disrupts the C-terminal region of Ankrd26 and leads to a truncation 
of the Ankrd26 gene. Animals homozygous for this gene trap allele 
(Ankrd26GT/GT) experience hyperphagia, obesity and insulin resistance. This 
phenotype was found to be caused by region specific changes in primary cilia in 
the brain, leading to an increased food intake and ultimately obesity.65 
 The mouse Ankrd26 gene is located on chromosome 6 and consists of 35 
exons spanning ~61 Kb. In the Ankrd26 gene trap mice, the β-galactosidase 
gene was inserted following exon 24, therefore, only the C-terminus of the gene 
is disrupted. Furthermore, characterization of the Ankrd26GT/GT animals showed 
that they express both mRNA and a protein corresponding to the Ankrd26-β-
galactosidase fusion product.55 Whether this protein retains functional activity or 
if the Ankrd26GT/GT mouse represents a full inactivation of Ankrd26 remains 
unclear. In order to faithfully study the effects if Ankrd26 loss in vivo, we decided 




5.2.1 Generation of the Ankrd26-/- mouse 
CRISPOR69 was used to optimize sgRNA selection on either side of a    
15 Kb region of Ankrd26 (deletion of exons 21-28). A repair template was 
generated with a BamHI cut site (GGATCC) flanked by 41 bp homology arms. 
Pronuclear injection was performed by the Transgenic mouse core laboratory at 
JHU/SOM. 
The presence of a deletion in the Ankrd26 gene was assessed by PCR. F 
Primer: KO_F2 (AAAGTGCCTCCTTCTGCTTG) , R Primer: KO_R4 
(CCCCAAAATCTCAGGAATGA). The presence of the WT allele was assessed 
using F Primer: KO_F3 (TTCCGAGAGCATTTTGTGTG) and R Primer: KO_R3 
(CACCCACACACACACTGGAT). The thermocycling parameters for the PCR 
were: 94 °C for 30 sec, 35 cycles of (94 °C for 30 sec, 55 °C for 30 sec, 72 °C for 
60 sec), and 72 °C for 5 min.. PCR product was digested with BamHI at 37 ºC for 
2 hrs and run on a 1 % agarose gel. Mice that had insertion of the repair template 
(evident by BamHI cleavage) were further validated by Sanger sequencing. 
 
5.3 Results 
5.3.1 Ankrd26-/- mice experience obesity 
 To see if the Ankrd26-/- mice experience an obesity phenotype like the 
Ankrd26GT/GT animals, Ankrd26 wild-type, heterozygous and homozygous 
knockout littermates were weighed each week for 40 weeks. Ankrd26-/- mice 
show an increased body weight compared to WT and heterozygous littermates 
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(Figure 5.1). This deviation was evident earlier in males compared to female 
animals; beginning at ~7 weeks in males compares to ~10 weeks in females. The 
differences in weight between Ankrd26-/- mice and their littermates was more 
pronounced in females, however. 
 
5.4 Discussion 
 The Ankrd26-/- mice have a similar obesity phenotype as that reported for 
Ankrd26GT/GT animals.55 The weight of Ankrd26-/- mice was not as high as that 
observed for Ankrd26GT/GT mice, nor was the difference between littermates as 
striking. However, these discrepancies may be due to the differences in feed 
used during each experiment. Whether the obesity phenotype observed in the 
Ankrd26-/- animals is due to cilia defects, as has been reported for Ankrd26GT/GT 
mice, has yet to be determined. The consistencies between the two models, lead 
us to speculate that this is likely the case. Additionally, these results suggests 
that despite the production of a fusion product, the Ankrd26GT/GT mice represent 
a full knockout of Ankrd26. 
 It would be interesting to see that affect centriole amplification has on 
Ankrd26-/- mice. Previous studies show that centriole amplification alone is 
sufficient to promote spontaneous tumorigenesis in mice.24 We would predict that 
loss of Ankrd26 and consequent inactivation of the pathway that prevents the 
proliferation of cells with extra centrioles would accelerate the process of 
tumorigenesis in animals with centriole amplification. 
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 Loss of PIDDosome components has been shown to lead to an increase 
in liver ploidy in vivo.70 Liver hepatocytes are natural polyploid and undergo 
cytokinesis failure during postnatal development.71 The PIDDosome restricts the 
ploidy of these cells to mostly 8N, however, when PIDD1, CRADD, CASP2 or 
P53 are lost, hepatocyte ploidy reaches 16N and even 32N in mice. Our lab has 
preliminary evidence that loss of Ankrd26 in both the Ankrd26-/- and Ankrd26GT/GT 
mice results in a similar increase in liver ploidy (unpublished). This provides 
physiological evidence that ANKRD26 functions to restrict the growth of cells with 
extra centrioles in vivo. 
 Defects in platelet formation or blood clotting has not been observed in 
either the Ankrd26-/- or Ankrd26GT/GT animal models. This underscores the idea 
that the thrombocytopenia-associated mutations in ANKRD26 are likely activating 








5.5 Figures for Chapter 5 
 
 
Figure 5.1 A. Schematic of the mouse Ankrd26 allele and the CRISPR deletion 
produced in Ankrd26-/- mice. B. Weights of female (left) and male (right) mice 
with the indicated Ankrd26 genotype. Data were collected across the indicated 
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